Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9HCN6
UPID:
GPVI_HUMAN
Alternative names:
Glycoprotein 6
Alternative UPACC:
Q9HCN6; Q9HCN7; Q9UIF2
Background:
Platelet glycoprotein VI, also known as Glycoprotein 6, plays a pivotal role in collagen-induced platelet adhesion and activation, crucial for thrombin and fibrin formation. This process is essential for the coagulation cascade, facilitating arterial and venous thrombus formation through a signaling pathway involving FcR gamma-chain, Src kinases, SYK, LAT, and PLCG2.
Therapeutic significance:
The protein's malfunction is linked to Bleeding disorder, platelet-type, 11, characterized by defective platelet activation. Understanding the role of Platelet glycoprotein VI could open doors to potential therapeutic strategies for managing bleeding disorders and preventing thrombus formation.